Eikon Therapeutics (EIKN) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Claim profile

EIKN · Stock Price

USD 9.17-5.83 (-38.87%)

Market Cap: $497.0M

Historical price data

Market Cap: $497.0MPipeline: 5 drugsPatents: 2Founded: 2019Employees: 101-250HQ: Millbrae, United States

Sector Ranking#23 in AI / Machine Learning #69 in Oncology (General)

Overview

Eikon Therapeutics' mission is to pioneer a new paradigm in drug discovery by directly observing the dynamic behavior of proteins in living cells, a field it terms 'dynamic biology.' The company has successfully built and scaled its proprietary platform, transitioned to a public company (NASDAQ: EIKN), and advanced a pipeline of five disclosed programs. Its strategy is to leverage its unique observational biology platform to identify and prosecute novel, high-value targets with the potential for first-in-class or best-in-class therapeutics.

OncologyImmunology

Technology Platform

An integrated platform combining high-throughput single-molecule tracking microscopy, automation, and proprietary machine learning to observe and quantify the dynamic behavior of individual proteins in living cells for novel drug target and candidate discovery.

Pipeline

5

5 drugs in pipeline

Drug	Indication	Stage
BDB001	Tumor, Solid	Phase 2
EIK1001 + Pembrolizumab + Paclitaxel + Pemetrexed + Carbopla...	NSCLC	Phase 2
EIK1004-001 (IMP1707-001)	Advanced Solid Tumors	Phase 1/2
IMP1734	Advanced Solid Tumor	Phase 1/2
BDB001 (EIK1001) + Atezolizumab	Tumor, Solid	Phase 1

Funding History

3

Total raised:$1.0B

Series D$350.7MUndisclosedFeb 26, 2025

Series B$517.8MT. Rowe PriceJan 15, 2022

Series A$148MThe Column GroupOct 15, 2021

Opportunities

Eikon's platform targets the vast 'undruggable' proteome by focusing on protein dynamics, potentially unlocking novel, high-value targets in oncology and immunology.

Success could validate a new discovery paradigm and create blockbuster therapeutics.

Risk Factors

The core risk is platform validation; the novel approach must yield clinically successful drugs.

The company also faces technical execution challenges in scaling its complex platform, significant future capital needs, and competitive IP threats.

Competitive Landscape

Eikon's focus on single-molecule protein dynamics is distinct from AI-driven phenomic screening (e.g., Recursion) and traditional structural biology. Its primary competition is the established drug discovery paradigm, though other platform biotechs and large pharma represent potential rivals or partners.